AstraZeneca Silent On Pfizer, Uses Growth And Pipeline To Speak For Its Prospects
AstraZeneca played it straight when reporting a strong second quarter, outlining a robust late stage pipeline, a growing list of early assets and collaborations, while avoiding “the elephant in the room” - predator Pfizer’s paused-pursuit of the U.K. pharma.
You may also be interested in...
Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.
The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.